You just read:

Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

News provided by

Shire plc

Apr 26, 2017, 01:00 ET